ストックスクリーナーアプリを入手
2.32
2.65%
0.06
前日終値:
$2.26
開ける：
$2.26
24時間の取引高:
1.02M
Relative Volume:
0.57
時価総額：
$154.34M
収益：
$488.00K
当期純損益:
$-41.44M
株価収益率:
-2.4946
EPS:
-0.93
ネットキャッシュフロー:
$-31.47M
1週間 パフォーマンス:
-4.92%
1か月 パフォーマンス:
-38.62%
6か月 パフォーマンス:
-51.16%
1年 パフォーマンス:
+1.31%
1日の値動き範囲:
$2.26
$2.3854
1週間の範囲:
$2.215
$2.56
52週間の値動き範囲:
$2.09
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
名前
Cardiff Oncology Inc
セクター
電話
858-952-7570
住所
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
CRDF を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.32 | 161.66M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2025-06-24 | 開始されました | Jefferies | Hold |
| 2024-09-06 | 開始されました | Craig Hallum | Buy |
| 2022-01-05 | 開始されました | William Blair | Outperform |
| 2021-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-09 | 再開されました | Maxim Group | Buy |
| 2020-10-22 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-08 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Cardiff Oncology Inc (CRDF) 最新ニュース
Breakout Traders Target Cardiff Oncology Inc. on Recovery Setup2025 Major Catalysts & Reliable Trade Execution Plans - beatles.ru
Is Cardiff Oncology Inc. the Top Chart Pick This WeekDollar Strength & Expert Verified Movement Alerts - kangso.co.kr
Cardiff Oncology Inc. Trading Near Value Zone — Recovery AheadWeekly Trend Recap & AI Powered Buy and Sell Recommendations - 선데이타임즈
Published on: 2025-08-19 02:38:05 - newsimpact.co.kr
Does Cardiff Oncology Inc. qualify in momentum factor screeningMarket Risk Report & Long-Term Growth Stock Strategies - Newser
Forecasting Cardiff Oncology Inc. price range with options data2025 Technical Patterns & AI Driven Price Predictions - Newser
Published on: 2025-08-15 06:29:30 - newsyoung.net
How Cardiff Oncology Inc. stock performs during market volatilityTrade Analysis Report & Expert Verified Stock Movement Alerts - Newser
New Product Launches: Will They Boost Cardiff Oncology Inc. Stock in 2025Long-Term Safety Investment Analysis Report - Newser
Institutional Tools Highlight Unusual Flow in Cardiff Oncology Inc.Quick Gain Stock Watch With Indicators Reviewed - beatles.ru
Clinical trial by SD company proves promising for drug that targets colorectal cancer - NewsBreak: Local News & Alerts
Q3 EPS Forecast for Cardiff Oncology Decreased by Analyst - Defense World
Analyzing drawdowns of Cardiff Oncology Inc. with statistical toolsDaily Technical Forecast for Quick Gains - Newser
Has Cardiff Oncology Inc. found a price floorReliable Setup Screener with Low Risk - Newser
What earnings revisions data tells us about Cardiff Oncology Inc.Minimal Risk Growth Investment Opportunity Analysis - Newser
Cardiff Oncology (CRDF) Projected to Post Earnings on Thursday - Defense World
Cardiff Oncology Price Target Cut to $10 by H.C. Wainwright. - AInvest
H.C. Wainwright lowers Cardiff Oncology stock price target on trial data - Investing.com Nigeria
Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom - insights.citeline.com
How does Cardiff Oncology Inc. generate profit in a changing economyAchieve breakthrough gains with smart trades - Jammu Links News
What is the dividend policy of Cardiff Oncology Inc. stockGet real-time alerts on top stocks - Jammu Links News
Why is Cardiff Oncology Inc. stock attracting strong analyst attentionFree Popular Stock Recommendations - Jammu Links News
Should I hold or sell Cardiff Oncology Inc. stock in 2025Maximize returns with disciplined investment techniques - Jammu Links News
What institutional investors are buying Cardiff Oncology Inc. stockUnstoppable profit momentum - Jammu Links News
Is Cardiff Oncology Inc. stock overvalued or undervaluedMarket-crushing stock picks - Jammu Links News
How strong is Cardiff Oncology Inc. company’s balance sheetFree Risk Assessment Services - Jammu Links News
What analysts say about Cardiff Oncology Inc. stockGrow your wealth with proven stock picks - Jammu Links News
What drives Cardiff Oncology Inc. stock priceUnrivaled growth potential - Jammu Links News
What is the risk reward ratio of investing in Cardiff Oncology Inc. stockAchieve consistent profits with proven methods - Jammu Links News
What catalysts could drive Cardiff Oncology Inc. stock higher in 2025Free Investment Risk Control - Jammu Links News
Is Cardiff Oncology Inc. a good long term investmentHigh-return market picks - Jammu Links News
When is Cardiff Oncology Inc. stock expected to show significant growthSuperior returns - Jammu Links News
Is Cardiff Oncology Inc. a growth stock or a value stockNavigate the market with precision tools - Jammu Links News
William Blair Raises Earnings Estimates for Cardiff Oncology - Defense World
Friday 8/1 Insider Buying Report: CRDF, MBIN - Nasdaq
Both Individual Investors Who Control a Good Portion of Cardiff Oncology, Inc. (NASDAQ:CRDF) Along With Institutions Must Be Dismayed After Last Week's 42% Decrease - 富途牛牛
Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data? - inkl
Cardiff Oncology Insiders Land Bargain With Gains Of US$244k - Yahoo Finance
Cardiff Oncology: Data Update Resolves Some Signals - Seeking Alpha
Cardiff Oncology (CRDF.O) Plummets 27%: What's Behind the Sharp Intraday Move? - AInvest
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Cardiff Oncology Shares Slide Over 26% In Premarket Trading After Mixed Q2 - Benzinga
Cardiff Oncology Plunges 26.59% on Earnings Miss - AInvest
Cardiff Oncology 2025 Q2 Earnings Financial Struggles as Net Income Declines 18.4% - AInvest
Cardiff Oncology Reports Q2 2025 Financial Results - TipRanks
Cardiff Oncology shares fall 26.89% after-hours after reporting a wider Q2 net loss. - AInvest
Cardiff Oncology shares plunge after Q2 earnings miss By Investing.com - Investing.com South Africa
Cardiff Oncology Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004) - TradingView
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Cardiff Oncology: Q2 Earnings Snapshot - San Francisco Chronicle
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com
Cardiff Oncology Inc (CRDF) 財務データ
収益
当期純利益
現金流量
EPS
Cardiff Oncology Inc (CRDF) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
| Levine James E. | Chief Financial Officer |
Dec 17 '24 |
Buy |
5.42 |
2,752 |
14,905 |
65,316 |
| Levine James E. | Chief Financial Officer |
Dec 18 '24 |
Buy |
5.00 |
2,400 |
12,000 |
67,716 |
| Levine James E. | Chief Financial Officer |
Dec 16 '24 |
Buy |
3.83 |
2,564 |
9,820 |
62,564 |
| TANNENBAUM RENEE P | Director |
Dec 12 '24 |
Buy |
3.42 |
10,000 |
34,224 |
20,000 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
350,115 |
910,299 |
1,047,876 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
11,500 |
29,900 |
1,059,376 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):